| 41.64 -0.05 (-0.12%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 54.3 | 1-year : | 58.18 |
| Resists | First : | 46.49 | Second : | 49.81 |
| Pivot price | 43.76  |
|||
| Supports | First : | 41.11 | Second : | 34.2 |
| MAs | MA(5) : | 42.27 |
MA(20) : | 44.89 |
| MA(100) : | 46.79 |
MA(250) : | 48.44 |
|
| MACD | MACD : | -1.3 |
Signal : | -1 |
| %K %D | K(14,3) : | 7.6  |
D(3) : | 6.3 |
| RSI | RSI(14): 30.8 |
|||
| 52-week | High : | 59.68 | Low : | 41.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SUPN ] has closed above bottom band by 8.0%. Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.68 - 43.09 | 43.09 - 43.33 |
| Low: | 40.74 - 41.28 | 41.28 - 41.61 |
| Close: | 41.03 - 41.9 | 41.9 - 42.42 |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Fri, 11 Sep 2026
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Thu, 10 Sep 2026
SUPN: Strong CNS portfolio and pipeline drive growth, with Qelbree and ZURZUVAE as key contributors - TradingView
Mon, 07 Sep 2026
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy? - Eastern Progress
Wed, 02 Sep 2026
Supernus Pharmaceuticals to Participate in September Investor Conferences - Yahoo Finance
Mon, 24 Aug 2026
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - Yahoo Finance
Fri, 07 Aug 2026
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 4,150 (K) |
| Shares Short P.Month | 4,850 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.72 |
| Profit Margin | -13.3 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | 0.3 % |
| Return on Equity (ttm) | -10.5 % |
| Qtrly Rev. Growth | 32.4 % |
| Gross Profit (p.s.) | 10.41 |
| Sales Per Share | 14.28 |
| EBITDA (p.s.) | 1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | 85 (M) |
| PE Ratio | -21.69 |
| PEG Ratio | 0 |
| Price to Book value | 2.34 |
| Price to Sales | 2.91 |
| Price to Cash Flow | 121.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|